New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized ...
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives ...
Dissolvable film BNT23001 led to about 40% higher cladribine exposure than tablets in a preclinical pig study, BioNxt ...
Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine ...
A Prescription Drug User Fee Act target date of January 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for epinephrine ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF ...
Please provide your email address to receive an email when new articles are posted on . Researchers called this the first study among children aged 1 to 4 years. The treatment group saw improved ...
For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...
TNX-102 SL is intended to be taken once at bedtime for the management of fibromyalgia. Treatment with TNX-102 SL (cyclobenzaprine HCl sublingual tablets) significantly reduced daily pain in patients ...
The latest update is out from BioNxt Solutions ( (TSE:BNXT) ).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results